Zinaxin with glucosamine: instructions for use, description, reviews, application

Manufacturer: Ferrosan
Active ingredients

Not indicated. See instructions

Pharmacological action

Not indicated. See instructions

Composition of Zinaxin with glucosamine
Indications for use of the drug Zinaxin with glucosamine
Release form of the drug Zinaxin with glucosamine
Use of the drug Zinaxin with glucosamine during pregnancy
Contraindications to the use of Zinaxin with glucosamine
Side effects of the drug Zinaxin with glucosamine
Method of administration and dosage of the drug Zinaxin with glucosamine
Storage conditions for the drug Zinaxin with glucosamine
Shelf life of the drug Zinaxin with glucosamine

Best before date

24 months

Vitamins with similar effects

Betulanorm (Capsule)
For the genitourinary system Life formula (Capsule)
Coffeeberry (Capsule)
Sana-Sol - Vitamin C (Oral tablets)
Pancreavit (Capsule)
Maxiflorum tea Grace with hibiscus and stevia (Powder for preparing a solution for oral administration)
Ginseng Doctor Theiss (Lozenges)

The description of vitamin Zinaxin with glucosamine is intended for informational purposes only. Before starting to use any drug, it is recommended to consult a doctor and read the instructions for use. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the project does not replace consultation with a specialist and cannot be a guarantee of the positive effect of the drug you use. The opinions of EUROLAB portal users may not coincide with the opinions of the site Administration.

Are you interested in vitamin Zinaxin with glucosamine? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

Attention! The information presented in the vitamins and dietary supplements section is intended for informational purposes and should not be a basis for self-medication. Some of the drugs have a number of contraindications. Patients need to consult a specialist!

If you are interested in any other vitamins, vitamin-mineral complexes or dietary supplements, their descriptions and instructions for use, their analogues, information about the composition and form of release, indications for use and side effects, methods of use, dosages and contraindications, notes about the prescription of the drug for children, newborns and pregnant women, price and consumer reviews, or you have any other questions and suggestions - write to us, we will definitely try to help you.

Zinaxin is a new safe drug for the treatment of osteoarthritis

In this regard, a strategy was adopted to protect the patient from adverse reactions when taking NSAIDs. One line of this strategy is associated with protecting the gastric mucosa by taking proton pump inhibitors, H2 receptor blockers, and synthetic prostaglandin analogues. The use of these drugs has led to a reduction in the risk of adverse events from the gastric and duodenal mucosa, but does not completely exclude their development. Also, their use does not affect the risk of erosive and ulcerative damage to the intestines, the risk of arterial hypertension, and renal dysfunction. The development by the pharmaceutical industry of a new class of NSAIDs - selective cyclooxygenase-2 inhibitors - was a new step in reducing the risk of adverse events. Their use, like gastroprotective therapy, led to a reduction in the risk of erosive and ulcerative damage to the gastrointestinal mucosa, but did not completely eliminate it, especially in the high-risk group: in elderly patients, with a history of peptic ulcers, long-term use of drugs, drugs in high therapeutic doses. Ambiguous results on the effect on the cardiovascular system when taking certain selective NSAID inhibitors have now been published in the literature based on the results of multicenter clinical trials. Thus, the problem of safe and effective treatment of osteoartitis requires further study and the development of new drugs and treatment methods. A new drug, Zinaxin, may become a new step in the treatment of osteoarthritis. Zinaxin is a combination drug that includes ginger root extract and glucosamine sulfate. A feature of the pharmacological form of Zinaxin is the use of nanotechnology in its production. The drug was created using a unique LipoCap™ technology, which makes it possible to obtain liposomal microcapsules that resemble a living cell in structure. The use of LipoCap™ technology allows for maximum bioavailability of the drug. Glucosamine sulfate is a chondroprotector with a proven effect, its effectiveness has been widely studied, and it is included in many chondroprotective drugs. New in the treatment of OA is the use of a standardized herbal extract of two carefully selected species of ginger (Zingiber officinale and Alpinia galanga). The beneficial effect of ginger on patients with symptoms of OA is described in folk and official medicine for the treatment of joint diseases; it is described in the pharmacopoeias of Great Britain, Japan, Switzerland, Austria, China, and Egypt. This fact served as a source for the development of the drug. The anti-inflammatory activity of ginger extract has been successfully proven in experimental studies on synoviocyte cultures. Ginger extract is a complex of chemicals including: 6-gingerol, 8-gingerol, 10-gingerol, gingerdione, gingerdiol, l-acetoxychavicol acetate, l'-acetoxyeugenol acetate, trans-p-coumaryl diacetate, coniferyl diacetate, l'- hydroxychavicol acetate, l'-hydroxychavicol, p-hydroxy-trans-cinnamaldehyde, p-methoxy-trans-cinnamylalcohol, and 3, 4-dimethoxy-trans-cinnamylalcohol. Synoviocytes isolated from 9 patients with osteoarthritis were used as an experimental model. The cells were cultured in a special medium. The expression of synoviocytes cyclooskigenase-2, interleukin-1, and prostaglandin E2 in tissue cultures activated by TNF-a was studied. It has been convincingly proven that adding ginger extract to the culture fluid at a dose of 100 μg/ml inhibits the expression of pro-inflammatory cytokines, suppresses the activity of cyclooxygenase, 5-lipoxygenase and reduces the production of pro-inflammatory prostaglandin E2. Another study [2] demonstrated the suppression of ginger extract and the activity of metalloproteinases in tissue culture of synoviocytes. Thus, experimental studies have convincingly proven the effect of ginger extract on the main links in the pathogenesis of osteoarthritis. The literature has accumulated sufficient material on the clinical use of Zinaxin. Bliddal et al. (2000) in a randomized study of 57 patients with OA showed a positive effect on the course of the disease. Altman and Marcussen (2001) in 230 patients with osteoarthritis with 3-month treatment with Zinaxin noted a decrease in pain during gonarthrosis. R.D. Altman and K.S. Marcussen (2001) in a randomized, double-blind, placebo-controlled, multicenter, 6-week study assessed the effectiveness and safety of a standardized and highly concentrated ginger extract in 261 patients with gonarthrosis. The effectiveness of ginger extract in the study group was 63% (50% in the placebo group). In patients receiving ginger extract, the severity of pain in a standing position decreased by 24.5 mm, in the placebo group - by 16.4 mm (p = 0.005), and there was also a significant decrease in the severity of pain when walking and standing. V.N. Kovalenko (2004) compared the effectiveness of Zinaxin (1 capsule 2 times a day) with diclofenac (daily dose 100 mg) during 3-month therapy. The study included 30 patients with gonarthrosis of radiological stages II–III according to Kellgren and Lawrence, aged 50–70 years. The authors noted improvement and significant improvement in 76.6% of patients receiving Zinaxin, and only 20% of those receiving diclofenac monotherapy. Patients receiving Zinaxin had significantly more pronounced analgesic and anti-inflammatory activity. During treatment, adverse events (stool upset, nausea) were noted in 2 patients taking Zinaxin. In patients taking diclofenac, adverse events (NSAID gastropathy, increased blood pressure) were observed in 26% of patients and required discontinuation of the drug and/or additional therapy. E.A. Yakimenko et al. (2004) used Zinaxin 1 capsule 2 times a day in 28 patients with stage II OA, and the patients continued to take NSAIDs. There was a positive trend in the Lequesne algofunctional index (92.9%). The severity of pain according to VAS decreased by more than 2 points in 78.6% of patients, with an average decrease of 33.3%. In 82.1% of patients, by the 7th–10th day of Zinaxin therapy, the daily dose of NSAIDs was reduced, and after 4 weeks, 57.1% of patients stopped taking NSAIDs. The authors noted the absence of adverse reactions. In their opinion, Zinaxin is a highly effective drug that significantly improves the quality of life and prognosis, and a safe drug for the treatment of OA. A.I. Dyadyk et al. published the results of the clinical use of Zinaxin in 76 patients with stage II–III OA. During treatment with Zinaxin, patients did not receive NSAIDs or local glucocorticoid therapy. Zinaxin in a standard dose of 1 capsule 2 times a day had a positive clinical effect in 88% of patients. The severity of pain according to VAS significantly decreased by an average of 22±11 mm, and joint mobility also significantly increased by 23±8 mm. The need for additional analgesic therapy with paracetamol remained only in 10 patients during the first 7 days. There were no cases of treatment discontinuation, and no severe adverse effects of Zinaxin were observed. Thus, a new drug has now emerged for the treatment of osteoarthritis, the effect of which is based on a complex effect on the pathogenesis of osteoarthritis. It has an anti-inflammatory and chondroprotective effect with isolated minor adverse events and in some patients can replace traditional NSAID therapy. ^ References 1. Altman RD, Marcussen KC Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum., 2001, 44(11): 2531–2538. 2. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis & Rheumatism 2001; 44:2531–2538. 3. Bliddal H, Rosetzsky A, Schlichting, P, Weidner, MS, Andersen, LA, Ibfelt, HH, Christensen, K, Jensen, ON, Barslev J. A randomized, placebo-controlled, cross-over study of ginger extracts and Ibuprofen in osteoarthritis. Osteoarthritis and Cartilage 2000;8:9–12. 4. Lindmark L., Sohrabi A., Phan PV, Polotsky AS, Overstreet MO, Hungerford DS and Frondoza CG Modulation of Pro-inflammatory Mediator and Metalloproteinase Expression in Human Synoviocytes//5th Symposium of ICRS Gent, Belgium, May 26–29 , 2004. 5. Dyadyk A.I., Shpilevaya N.I., Zdikhovskaya I.I., Boeva I.A., Khristulenko A.L. The herbal preparation zinaxin is one of the important components in the treatment of osteoarthritis. 6. Kovalenko V.N., Bortkevich O.P., Timoshenko E.Yu. Evaluation of the effectiveness and safety of the use of the drug zinaxin in the treatment of patients with osteoartosis of the knee joints: data from an open three-month study // Ukrainian Rheumatological Journal, No. 4(18), 2004. 7. Polivoda S.N., Cherepok A.A., Rekalov D.G. Modern possibilities and prospects for pharmacotherapy of osteoarthritis. 8. Carmelita G., Frondoza CG, Sohrabi A., Polotsky A., Phong V. Phan, Hungerford DS, and Lindmarkan L. // In vitro screening assay for inhibitors of proinflamatory mediators in herbal extracts using human synoviocyte cultures //In Vitro Cell. Dev. Biol—Animal 40:95–101, March and April 2004. 9. Shamuilova M.M., Sosnin P.S., Aliluev A.A., Sugaipov A.A. Rational pharmacotherapy of osteoarthritis // Remedium, 2007, No. 11, p. 28–30. 10. Yakimenko E.A., Zakatova L.V., Kravchuk O.E., Dec V.V., Antipova N.N., Dolzhenkova I.M., Vasilets V.V., Zagorodnaya L.I. Study of the effectiveness and safety of the use of zinaxin in the complex therapy of patients with osteoarthritis //Ukrainian Therapeutic Journal, 2004, No. 1, p. 103–106.